Symbols

ANIK

Anika Therapeutics·NASDAQ

--(--)

ANIK fundamentals

ANIK Q4 2025 Earnings

Anika Therapeutics (ANIK) released its earnings on Feb 26, 2026: revenue was 30.61M (YoY +0.04%), beat estimates; EPS was 0.31 (YoY +1133.33%), beat estimates.

Revenue / YoY

30.61M

+0.04%

EPS / YoY

0.31

+1133.33%

Report date

Feb 26, 2026

ANIK Earnings Call Summary for Q4,2025

Commercial Channel Dominance: 15% FY2025 commercial revenue growth (22% Q4) driven by international OA pain and Integrity, offsetting OEM decline.
Pipeline Momentum: Hyalofast FDA engagement, Cingal NDA on track, Integrity post-market study 50% enrolled with $6M FY2025 revenue.
Financial Strength: 63% Q4 gross margin, $11.2M operating cash flow, $57.5M ending cash; 2026 EBITDA target 5%-10% of revenue.
Sustainability Focus: High 50s% gross margin target, $2.5M annualized G&A savings, and $10.7M share buyback completion by Q2 2026.

Earnings

EPS

Revenue

Revenue & Expenses

ANIK has released its 2025 Q4 earnings report, with revenue of 30.61M, reflecting a YoY change of 0.04%, and net profit of 292.00K, showing a YoY change of 101.34%. The Sankey diagram below clearly presents ANIK's revenue sources and cost distribution.

Key Indicators

Anika Therapeutics (ANIK) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Anika Therapeutics (ANIK)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Anika Therapeutics (ANIK)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Anika Therapeutics (ANIK)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown